Session Chair Profile
Dr. Jennifer Lovejoy is a senior executive and biobehavioral scientist with deep experience in personalized medicine. During her academic career, Dr. Lovejoy held the Manship Endowed Professorship in Diabetes at LSU's Pennington Biomedical Research Center. She is a Past-President of the Obesity Society and has published over 80 peer-reviewed papers on her research. More recently, Dr. Lovejoy was Chief Translational Science Officer at Arivale, a precision medicine startup uniting systems biology and behavioral science to help consumers optimize wellness. Currently, she is the SVP, Head of Research at Calibrate, a company that combines FDA-approved weight loss medications with personalized lifestyle interventions to help individuals improve metabolic health.
Dr. Lu Qi is Director of Tulane Personalized Health Institute, and Director of Tulane University Obesity Research Center. His research focuses on nutritional epidemiology, nutrigenomics and nutrigenetics of obesity, diabetes, and cardiovascular diseases. As the Principal Investigator, he has led more than ten projects funded by NIH, American Heart Associations, and other funding agencies. He has published more than 400 scientific publications in peer-reviewed journals, including the high-impact journals such as N Engl J Med., JAMA, BMJ, Circulation, J Am Coll Cardiol., Eur Heart J., Nature, Nature Genetics and Nature Medicine. He has also written more than 10 book chapters and edited a textbook entitled ‘Gene-Environment Interactions and Human Diseases’. Dr. Qi is a fellow of American Heart Association (FAHA), American College of Nutrition (FACN), and The Obesity Society (FOS).
For ~30 years Christopher Gardner has studied what to consume and to avoid for optimal health, and how best to motivate individuals to achieve healthy dietary behaviors. Some of the dozens of human nutrition intervention trials he has conducted include studies of garlic, omega-3 fats, soy phytoestrogens and antioxidants. Among his most cited studies are the A TO Z (JAMA 2007) and the DIETFITS (JAMA 2018) weight loss diet trials. The DIETFITS trial examined the possibility that a 3-SNP multilocus genotype would predict differential weight loss success on a Healthy-Low-Fat vs. a Healthy-Low-Carb diet among more than 600 overweight and obese adults. His interests in this area of personalized nutrition continue with his participation in the Trans-NIH Consortium: Randomized Controlled Trials of Lifestyle Weight Loss Interventions for Genome-wide Association Studies. He is also working on personalized nutrition explorations with other investigators.
DNA-based Weight Loss Interventions: What Have We Learned?
The 2018 DIETFITS study tested the hypothesis that a 3-SNP genotype pattern would be an effect modifier of weight loss on a healthy low-fat vs. a healthy low-carb diet. The hypothesis was not supported. NIH convened a consortium too look at this question across studies. What have they learned?